Key result
LAAC provides non-inferior thromboembolic protection versus OACs in AF while reducing long-term bleeding.
Why the study?
OACs remain standard for stroke prevention in AF but carry bleeding risk, intolerance, and adherence issues, prompting evaluation of LAAC as an alternative.
Does percutaneous left atrial appendage closure prevent thromboembolic events and reduce bleeding compared to oral anticoagulants in patients with atrial fibrillation?
Systematic Review
Does percutaneous left atrial appendage closure prevent thromboembolic events and reduce bleeding compared to oral anticoagulants in patients with atrial fibrillation?
Answers are grounded in this paper and cite their sources.
LAAC provides non-inferior thromboembolic protection compared with oral anticoagulants while reducing long-term bleeding events, making it a viable alternative for patients with atrial fibrillation at elevated bleeding risk.
Background Oral anticoagulants (OACs) remain the standard strategy for stroke prevention in atrial fibrillation (AF) but are limited by bleeding risk, intolerance, and long-term adherence challenges. Left atrial appendage closure (LAAC) has emerged as a catheter-based alternative for thromboembolic prevention in non-valvular AF. This systematic review evaluated the comparative efficacy and safety of LAAC versus OAC therapy in patients with AF. Methods PubMed and Embase were systematically searched for randomized controlled trials (RCTs) comparing percutaneous LAAC with OACs, including direct oral anticoagulants (DOACs) and warfarin, in patients with AF. Results Four pivotal randomized trials (PROTECT AF, PREVAIL, PRAGUE-17, and OPTION) were included. Compared with DOAC therapy, LAAC demonstrated non-inferiority for the composite endpoint of all-cause death, stroke, or systemic embolism in OPTION and for the primary composite outcome in PRAGUE-17. LAAC was associated with significantly lower non-procedural bleeding compared with DOACs in OPTION and PRAGUE-17. Compared with warfarin, LAAC achieved non-inferiority for ischemic stroke or systemic embolism beyond 7 days after randomization in PREVAIL and reduced long-term cardiovascular mortality in PROTECT AF. Procedure-related complications declined with increasing operator experience. Conclusion LAAC provides non-inferior thromboembolic protection compared with OAC therapy while reducing long-term bleeding events in selected patients with AF. LAAC represents an important alternative for patients at elevated bleeding risk or with contraindications to long-term anticoagulation.
No takes yet. Share an insight, caveat, or question.
(293917) et al. (2026) conducted a systematic review in Atrial Fibrillation. Left atrial appendage closure (LAAC) vs. Oral anticoagulants (OACs) was evaluated on Composite endpoint of all-cause death, stroke, or systemic embolism (varies by trial). Left atrial appendage closure provided non-inferior thromboembolic protection compared with oral anticoagulants while reducing long-term bleeding events in selected patients with AF.
Synapse has enriched 10 related papers. Consider them for comparative context: